New immune target to treat cardiovascular disease discovered

The protein, suPAR, has been found to cause atherosclerosis and kidney disease, raising potential for new treatments.

5:00 AM

Author | Noah Fromson

suPAR cells enter the blood vessel wall and accelerate the development of atherosclerosis
Justine Ross, Michigan Medicine

For the longest time, clinicians have treated cardiovascular disease by focusing on diabetes and blood pressure control, reducing cholesterol using medications like aspirin and statins.

Despite these measures, heart disease remains the number one cause of death in the United States, with many patients having heart attacks even after their risk factors are controlled, says Salim Hayek, M.D., physician-scientist and medical director of the University of Michigan Health Frankel Cardiovascular Clinics.

But a study led by Michigan Medicine has uncovered a protein produced by the immune system that causes atherosclerosis – the hardening of arteries that affects over a billion people worldwide – which offers the promise of new treatments.

SEE ALSO: SuPAR identifies patients at high risk of blood clot formation (uofmhealth.org)

“Targeting the immune component central to the development of atherosclerosis is the Holy Grail for the treatment of heart disease,” said Hayek, senior author of the study “This is the first time that a component of the immune system is identified that meets all the requirements for being a promising treatment target for atherosclerosis.”

This protein, called soluble urokinase plasminogen activator receptor, or suPAR, is produced by the bone marrow. It acts as a regulator, essentially a thermostat for the activity of the immune system, or “immunostat”.

Past studies have shown suPAR to be a marker of cardiovascular disease. But this study, published in the Journal of Clinical Investigation, is the first evidence showing that the protein actually causes atherosclerosis when at high levels.

Three-pronged findings

First, the research team analyzed the Multi-Ethnic Study of Atherosclerosis, which consists of over 5,000 people without known cardiovascular disease and found that those who had higher suPAR levels were much more prone to develop atherosclerosis and experience cardiovascular events, regardless of their underlying risk factors.

SEE ALSO: Immune marker suPAR high in patients with heart failure, predicts risk and death

Then, the investigators did a genetic study of 24,000 people to find whether certain genetic variations affected levels of suPAR in blood. They discovered a specific variant in the gene PLAUR that codes for suPAR, and people with that genetic variant tended to have higher suPAR levels. Most importantly, that genetic variant was linked to atherosclerosis in a Mendelian randomization analysis of 500,000 participants in the UK Biobank, which was replicated in two other large data sets.

"This is the first time that a component of the immune system is identified that meets all the requirements for being a promising treatment target for atherosclerosis."

"We also found that participants lacking a copy of the PLAUR gene have lower risk of heart disease,” said first author and geneticist George Hindy, M.D., Ph.D., of Regeneron Genetics Center. “Altogether, the genetic data is truly compelling for high suPAR being a cause of atherosclerosis.”

Finally, in mouse models with high suPAR levels, researchers saw a dramatic increase in atherosclerotic plaques of mouse aortas compared to mice with normal suPAR levels.

Like Podcasts? Add the Michigan Medicine News Break on Spotify, Apple Podcasts or anywhere you listen to podcasts.

“Even prior to developing atherosclerosis, the mouse aortas with high suPAR levels contained more inflammatory white blood cells, and the immune cells circulating in blood were in an activated state, or ‘attack-mode,’” said Daniel Tyrrell, Ph.D., co-first author and research fellow at the U-M Health Frankel Cardiovascular Center. “High suPAR levels appear to activate the immune cells and prime them to overreact to the high cholesterol environment, causing these cells to enter the blood vessel wall and accelerate the development of atherosclerosis.”

What is unique about this study, Hayek says, is that it brings to light high-quality clinical, genetic and experimental data – all pointing to suPAR as a cause of atherosclerotic disease.

“Now, we’re looking into developing treatments to reduce suPAR levels safely as a strategy to prevent and treat heart disease, especially since traditional therapies for atherosclerosis have no impact on suPAR,” he said.

suPAR linking kidney and cardiovascular disease

The study dovetails findings that suPAR is known to be a pathogenic factor that causes kidney disease, which impacts one in seven Americans. People often experience the two conditions together: two-thirds of people with kidney disease are affected by cardiovascular disease, and over 40% of patients with cardiovascular disease have signs of kidney disease.

“This paper places suPAR as the link between kidney and cardiovascular disease; a common factor causing both through this inappropriate, persistent activation of the immune system,” said co-author Jochen Reiser, M.D., Ph.D., chair of the Department of Medicine at Rush University and an expert in the study of suPAR. “This is pointed out in the Mendelian randomization genetic analysis done by the investigators, showing that high suPAR is also linked to kidney disease.”

For both conditions, suPAR has long been known as a biomarker for poor outcomes and disease progression. In a 2020 study, Hayek’s team found that suPAR can worsen acute kidney injury and that blocking suPAR prevents it. A recent study led by Hayek found that levels of protein are high in patients with heart failure and predict death for patients.

Research into suPAR’s role in health and disease has advanced rapidly in the past 10 years. Hayek says suPAR has great potential to be a successful treatment target for cardiovascular and kidney disease. His lab has already begun work designing anti-suPAR therapies and planning clinical trials.

“My hope is that we are able to provide these treatments to our patients within the next three to five years,” he said. “This will be a game changer for the treatment of atherosclerotic and kidney disease”.

Live your healthiest life: Get tips from top experts weekly. Subscribe to the Michigan Health blog newsletter

Headlines from the frontlines: The power of scientific discovery harnessed and delivered to your inbox every week. Subscribe to the Michigan Health Lab blog newsletter

Additional authors include Alexi Vasbinder, Ph.D., R.N., Ayse Bilge Ozel, Ph.D., Sarah Graham, Ph.D., Grace H. Holton, Kingsley-Michael Amadi, Grace K. Erne, Annika Tekmulla,  Anis Ismail, M.D., Christopher Launius, Lili Zhao, Ph.D., Venkatesh L. Murthy, M.D., Ph.D., David J. Pinksy, M.D., Cristen Willer, Ph.D., Daniel R. Goldstein, M.D., Karl C. Desch, M.D., all of University of Michigan. Other authors listed in online publication.

The study was funded by the The National Heart, Lung, and Blood Institute, the Michigan Institute for Clinical & Health Research (MICHR), and the Gilead Sciences Research Scholar Program in Cardiovascular Disease.

Hayek and the University of Michigan have patents filed for the use of suPAR levels in the management of cardiovascular disease and the use anti-suPAR therapies as a strategy to prevent and treat atherosclerosis. Hayek and Reiser are scientific advisory board members of Walden Biosciences, a company devising therapeutics targeting suPAR in kidney disease. Hindy, Haas, Nielsen and Lotta receive salary, stocks and stock options from Regeneron Pharmaceuticals, Inc. Eugen-Olsen is a co-founder, shareholder, and chief scientific officer of Virogates and a named inventor on patents related to suPAR.

Paper cited: “Clinical, genetic, and experimental increase in soluble urokinase plasminogen activator receptor levels promotes atherosclerosis,” The Journal of Clinical Investigation. DOI: 10.1172/JCI158788

Health Lab word mark overlaying blue cells
Health Lab

Explore a variety of health care news & stories by visiting the Health Lab home page for more articles.

Media Contact Public Relations

Department of Communication at Michigan Medicine

[email protected]

734-764-2220

Stay Informed

Want top health & research news weekly? Sign up for Health Lab’s newsletters today!

Subscribe
Featured News & Stories young adult male hugging blonde haired dog
Health Lab
Cutting edge brain neurostimulator device significantly reduces 21-year-old’s seizures
A 21-year-old patient benefits from a novel application of responsive neurostimulation, also known asRNS, surgery to reduce seizures from drug-resistant epilepsy.
Well-Being at Michigan Medicine podcast - a part of the Michigan Medicine Podcast Network.
Well-Being at Michigan Medicine
Episode 1: The Enterprise Triad
The inaugural episode of Well-Being at Michigan Medicine has Dr. Elizabeth Harry welcoming the organization’s triad leadership – Dr. Paul Lee of the U-M Medical Group, Julie Ishak, M.S.N., the chief nurse executive, and Dr. Charlie Reuland, the chief operations integration officer overseeing operations at the clinical enterprise. Some of the topics that the quartet discuss include fostering a culture of people feeling cared at work and how it can make a difference in patients’ lives, recognizing stress and structural issues and how to stave off burnout, and reducing cognitive load. Learn more about the host of Well-Being at Michigan Medicine, Dr. Elizabeth Harry. Episode guests: • Julie Ishak, M.S.N., R.N. • Paul Lee, M.D., J.D. • Charlie Reuland, Sc.D., M.H.S.
A Michigan Medicine employee reads to a baby in the Brandon Neonatal Intensive Care Unit.
News Release
$10M Mott Foundation grant will help expand complex care spaces at C.S. Mott Children's Hospital
A $10 million grant from the Charles Stewart Mott Foundation to U-M will enable C.S. Mott Children's Hospital to renovate space within its NICU and PCTU.
close up of sensor
Health Lab
Stent sensor can warn of blockages in the bile duct
Currently, medical providers monitor biliary stent blockages through blood tests, meaning the problem must be significant enough for the body to notice. A sensor within the stent could enable doctors to recognize that bacterial sludge is accumulating and intervene before the patient begins to fall ill.
Health Lab Podcast in brackets with a background with a dark blue translucent layers over cells
Health Lab Podcast
Tips for Hosting Allergy-Safe Holidays
Precautions are crucial — even lifesaving — when feeding guests with dietary restrictions. Simple strategies can help avoid issues at the dinner table.
Female Urologist
Health Lab
A urologist explains women’s most common urological concerns — and how to treat them
Women with urological issue may not know how common — and treatable — they are, which keeps many from seeking proper care. But help is available.